Please assess the completion status of the following clinical trial:

Trial Title: Transdermal Clonidine in the Treatment of Severe Hyperemesis Gravidarum

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Gestational age 6-12 weeks and a major grade of HG clinical severity defined as follows:~* a PUQE score index ≥ 13 associated to one or more of the following conditions:~* weight loss \> 5% of pregravidic weight,~* electrolyte disturbances,~* dehydration,~* duration of symptoms \> 10 days ,~* inadequate food and drink intake~Exclusion Criteria:~* Language barrier.

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- clonidine first - placebo second (Type: OTHER): in this group patients are treated with transdermal clonidine first for 5 days then switch to placebo for 5 days
- placebo first - clonidine second (Type: OTHER): in this group patients are treated with placebo first for 5 days then with transdermal clonidine for next 5 days

Based on this trial design, predict the completion outcome and termination type (if applicable).